Featured Research

from universities, journals, and other organizations

Researchers See Alternative To Common Colorectal Cancer Drug

Date:
June 22, 2008
Source:
Massachusetts Institute of Technology
Summary:
A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, researchers have found.

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.

"This compound, the antitumor properties of which were established in mice over 20 years ago, emerged in our search for platinum anticancer drug candidates with cellular uptake properties analogous or superior to those of oxaliplatin," said Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT and senior author of a paper on the work appearing in the June 16 online edition of the Proceedings of the National Academy of Sciences.

cDPCP could become an alternative to oxaliplatin, which was approved by the FDA in 2004 and is usually the first therapeutic line of defense against colorectal cancer. More than 100,000 Americans are diagnosed with colorectal cancer every year, making it the fifth most common cancer in the United States, according to the National Cancer Institute.

Oxaliplatin and cisplatin fight tumors by entering the cell nucleus and binding to DNA, damaging it and inducing cell death, said Ryan Todd, a graduate student in chemistry and co-lead author of the paper.

cDPCP kills cells in a similar way. However, the key difference is that while oxaliplatin and cisplatin can enter almost any cell, causing harmful side effects, cDPCP requires the assistance of organic cation transporters (OCTs) embedded in the cell membrane.

That help is required because cDPCP is a positively charged molecule. Working with cultured human cells, the researchers found that cDPCP engages the assistance of OCT1 and OCT2, which are present in the colon. Thus, cDPCP could be specifically targeted to colorectal tumors.

"cDPCP may affect other cells in the body, but there could be greater targeting of colorectal cancer cells because of uptake by the transporters," said graduate student Katherine Lovejoy, co-lead author of the paper.

cDPCP's anticancer activity was first observed in mice 20 years ago, but it was never tested in humans, in part because it was not expected to readily cross cell membranes.

Researchers in Lippard's lab, working with other cancer researchers at MIT, have started studying the effectiveness of cDPCP in mice expressing human colorectal tumors, and they also hope to launch clinical trials in humans.

Other authors of the paper are Michael McCormick, an MIT graduate student in chemistry, Shuzhong Zhang and Kathleen Giacomini of the University of California at San Francisco, J. Alejandro D'Aquino of Brandeis University, and Joyce Reardon and Aziz Sancar of the University of North Carolina School of Medicine.

The research was funded by the National Cancer Institute and the National Science Foundation.


Story Source:

The above story is based on materials provided by Massachusetts Institute of Technology. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts Institute of Technology. "Researchers See Alternative To Common Colorectal Cancer Drug." ScienceDaily. ScienceDaily, 22 June 2008. <www.sciencedaily.com/releases/2008/06/080617102843.htm>.
Massachusetts Institute of Technology. (2008, June 22). Researchers See Alternative To Common Colorectal Cancer Drug. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2008/06/080617102843.htm
Massachusetts Institute of Technology. "Researchers See Alternative To Common Colorectal Cancer Drug." ScienceDaily. www.sciencedaily.com/releases/2008/06/080617102843.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins